Search Results
Onco
Daily
Facebook
RSS
X
Youtube
Linkedin
October, 2024
October 2024
M
T
W
T
F
S
S
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
« Sep
MD Anderson Cancer Center
Sep 2, 2023, 19:00 |
Opinion
Naveen Pemmaraju: Please join us for a special episode of Heme Reports!
Naveen Pemmaraju, the Director of the Leukemia - Cancer Network at the MD Anderson Cancer Center,…
Sep 1, 2023, 18:38 |
Drugs
Hagop Kantarjian: Now out in American Journal of Hematology reporting Ph II trial of CLIA +/- Sorafenib in newly diagnosed AML.
Hagop Kantarjian, Department Chair, Department of Leukemia, Division of Cancer Medicine at MD Anderson Cancer…
Aug 31, 2023, 19:04 |
Insight
Naveen Pemmaraju: Ph2 CLIA with or without sorafenib for upfront AML therapy.
Naveen Pemmaraju, the Executive Director of Cancer Medicine at the MD Anderson Cancer Center, recently…
Aug 31, 2023, 18:52 |
Insight
Nitin Jain: Excited to share preclinical data with CRLF2 bispecific antibody for CRLF2-rearranged B-ALL.
Quoting Nitin Jain, the Director of Leukemia CAR-T Program at the MD Anderson Cancer Center:…
Aug 31, 2023, 18:41 |
Blog
Mark Clemens: Save the Date: Upcoming OR Manager Conference in Nashville, September 18-20
Mark Clemens, the Associate Vice President of Perioperative Services at the University of Texas MD…
Aug 30, 2023, 17:44 |
Opinion
Naveen Pemmaraju: Wonderful gathering of thought leaders, friends, colleagues in our myeloid leukemia field this weekend at the International Workshop on Acute Leukemias 2023 in San Diego!
Aug 30, 2023, 17:42 |
Opinion
Emma B. Holliday: Is it lame to want what you already have?
Quoting Emma B. Holliday, a Radiation oncologist at the University of Texas MD Anderson Cancer…
Aug 29, 2023, 18:18 |
Blog
Peter Pisters: We had an inspiring discussion with Ochsner Health Board of Directors and leaders.
Peter Pisters, the President of MD Anderson Cancer Center, recently tweeted: "Today we had an…
Aug 27, 2023, 19:01 |
Insight
Naveen Pemmaraju: New paper alert from our group led by our doctor Montalban Bravo and professor Garcia Manero.
Quoting Naveen Pemmaraju, the Executive Director of Cancer Medicine at the MD Anderson Cancer Center,…
Aug 27, 2023, 18:50 |
Insight
Anirban Maitra: The phase 1 data of Genentech’s KRAS G12C inhibitor Divarasib was published yesterday in NEJM.
In a Twitter post by Anirban Maitra, a Professor of Pathology and Translational Molecular Pathology,…
138
139
140
141
142
All:
1459
Posts:
1391 - 1400
Targeted Therapy vs Immunotherapy: Which Is Right for You, Key Differences & Similarities
ASTRO 24: 15 Posts Not to Miss From Day 2
Julia Louis-Dreyfus and Breast Cancer: How She Went Against, How She Survived, and More
ASTRO24: 20 Posts Not To Miss From Day 1
Fran Drescher and Uterine Cancer: How She Went Against, How She Survived, and More
Special Coverage
ASCO Annual Meeting
May 30 - June 4, 2024
Yvonne Award 2024
May 31, 2024
OncoThon 2024, Online
Feb. 15, 2024
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Facebook
RSS Feed
X
Linkedin
Youtube